Skip to main content

Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments.

Project description

Decreasing resistance to an important treatment for tuberculosis

Field of science

  • /medical and health sciences/clinical medicine/pneumology/tuberculosis

Call for proposal

H2020-JTI-IMI2-2018-16-single-stage
See other projects for this call

Funding Scheme

IMI2-RIA - Research and Innovation action

Coordinator

BIOVERSYS AG
Address
Hochbergerstrasse 60 C Technologiepark Basel
4057 Basel
Switzerland
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 6 926 375

Participants (1)

GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL
Spain
EU contribution
€ 0
Address
C/ Severo Ochoa Numero 2 Parque Tecnologico De Mad
28760 Tres Cantos Madrid
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)